South Korea companies to invest 12 million USD in Israeli innovation

South Korean companies invested 12 million USD into two companies made possible by tech-transfer from the Weitzman institute of Science.

March 24, 2019 18:23

Mice [Illustrative]. (photo credit: INGIMAGE)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


South Korean Yozma Group Asia and group BioLeaders Corporation announced they will invest roughly 12 million USD in Israeli anti-cancer technology based on technology developed at the Weizmann institute of Science, the Institute reported on Tuesday.

Yozma Group Asia will invest 2 million USD in On-Sight Medical Inc., which is currently developing an easy-to-use ultrasound technology that patients may use on their own and analyze the results. Once in service, the technology will solve the deficit in the numbers of trained technicians as well as help ease the workload in hospitals.

Another company to receive investments from Korea is BioLeaders, which is currently developing an anti-cancer drug.

The cancer therapy will be founded on the discovery by Israeli scientists that the p53 protein is disabled in roughly two thirds of cancer types.

Israeli scientists developed a new protein [peptide] which restores p53 protein's normal functions. During the therapy in lab mice with human cancer tumors, it was reported that they experienced a diminishing of the tumors and, in some cases, their complete disappearance.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Emtanis Shihadeh of UAL-Balad
April 25, 2019
Meet the new MK: Emtanis Shihadeh of UAL-Balad